Optos ushers in new generation of imaging with MonacoPro ultra-widefield and OCT

News
Article

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

Image credit: AdobeStock/Panama

(Image credit: AdobeStock/Panama)

Optos is looking to build upon the legacy of the Monaco with MonacoPro, a next-generation ultra-widefield scanning laser ophthalmoscopy (SLO) and spectral domain retinal imaging solution. The fresh take maintains the quality and features eye care providers and techs love about the original Monaco and adds enhanced OCT image quality and AreaAssist to improve diagnostic precision and workflow efficiency around the clinic.1

“MonacoPro represents our commitment to continuous innovation in ophthalmic imaging,” Optos Chief Executive Officer Robert Kennedy said in a press release. “With new advancements in automation, and data analysis, we are empowering clinicians with tools that enhance efficiency and diagnostic confidence while maintaining our industry-leading ultra-widefield imaging capabilities.”

Key product features of MonacoPro

Enhanced OCT image quality provides detailed and precise retinal images for a clearer and more accurate look at retinal layers, which aids in diagnosis and treatment planning. When used in conjunction with the integrated 200° single-shot optomap imaging, MonacoPro captured images that lead to an improved 29.4% identification of macular pathology when compared with fundus alone.2

MonacoPro will be available to ship in March 2025. (Image courtesy of Optos)

MonacoPro will be available to ship in March 2025. (Image courtesy of Optos)

AreaAssist is a brand-new tool that aims to enhance retinal imaging workflows. AreaAssist identifies continuous areas of matching color to be measured automatically. Additionally, technicians and providers can easily adjust the sensitivity of the area using the familiar “click-and-drag” mouse motion. By doing these tasks during the imaging process, it reduces time-consuming manual tasks.

In addition to the new features, MonacoPro features one of the largest reference databases in retinal imaging. The Optos Reference Database in the US market, expanded on the MonacoPro, includes 879 eyes and filters results based on optic disc sizes and age. Organizing data based on size of the optic nerve head is a more effective approach than other criteria for identifying relevant population data, and therefore diagnostic precision, one study reports.3

Optos’ launch of MonacoPro highlights the company’s ongoing dedication to advancing retinal imaging technology for improved diagnosis, management of ocular pathology, and eye care provider confidence. This new technology combines efficiency, clinical accuracy, and improved patient outcomes in hopes of becoming an indispensable tool in the eye care provider’s armamentarium.

MonacoPro will begin shipping in March 2025. To learn more, visit the Optos website.

References
  1. Optos unveils MonacoPro: The next generation in integraged ultra-widefield and OCT retinal imaging. Optos. Press release. Published February 14, 2025. Accessed February 18, 2025. https://www.optos.com/press-releases/optos-unveils-monacopro/
  2. Aiello LP, Jacoba CMP, Ashraf M, et al. Integrating macular optical coherence tomography with ultrawide-field imaging in a diabetic retinopathy telemedicine program using a single device. Retina. 2023;43(11):1928-1935. doi:10.1097/IAE.0000000000003883
  3. Salazar P, Rozwat A, Speilburg A, Chaglasian MA, Sinai M. Optical coherence tomography measurement correlations with age and optic disc size. Invest Ophthal Vis Sci. June 2024;65:4848
Recent Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
The relationship between outer retinal integrity, subretinal fluid may affect treatment outcomes
Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy
Measuring retinal blood flow biomarkers using OCT Doppler
© 2025 MJH Life Sciences

All rights reserved.